Publications for Karen P. Seiter karen_seiter@nymc.edu

NYMC School of Medicine
  • Lancet, J., Uy, G., Cortes, J., Newell, L., Lin, T., Ritchie, E., . . . Seiter K. (2016). Cpx-351 treatment of previously untreated older AMI patients with high risk AMI markedly increases the response rate over 7+3 in patients with FLT3 mutations. Haematologica, 101(Suppl 1), 186. This material can be found here.

  • Linder, K., Gandhiraj, D., Hanmantgad, M., Seiter, K., & Liu, D. (2016). Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: HyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental Hematology & Oncology, 5, 20. doi:10.1186/s40164-016-0051-4

  • Mamorska-Dyga, A., Wu, J., Khattar, P., Ronny, F. M., Islam, H., Seiter, K., & Liu, D. (2016). Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: A case report. Stem Cell Investigation, 3, 8. doi:10.21037/sci.2016.03.02

  • Martinelli, G., Pappayannidis, C., Yee, K., Vey, N., Drummond, M., Kelly, K., . . . Seiter, K. (2016). Phase 1B results of idasanutlin plus cytarabine (ARA-C) in acute myeloid leukemia (AML) patients (PTS). Haematologica, 101(Suppl 1), 187.

  • Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., . . . Seiter, K. (2016). Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica, 101(5), e185-e188. doi:10.3324/haematol.2015.139717

  • Savooji, J., Shakil, F., Islam, H., Liu, D., & Seiter, K. (2016). CD34+ therapy-related acute promyelocytic leukemia in a patient previously treated for breast cancer. Stem Cell Investigation, 3, 7. doi:10.21037/sci.2016.03.03

  • Seiter, K. (2016). Therapy for relapsed acute lymphoblastic leukemia: Still a role for standard chemotherapy regimens? Leukemia Research, 41, 1-2. doi:10.1016/j.leukres.2015.12.004

  • Seiter, K., Ahmed, N., Shaikh, A., Baskind, P., & Liu, D. (2016). CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. Leukemia Research, 46, 74-78. doi:10.1016/j.leukres.2016.04.015

  • Seiter, K., Stiefel, M. F., Barrientos, J., Shaikh, A., Ahmed, N., Baskind, P., & Liu, D. (2016). Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support. Stem Cell Investigation, 3, 27. doi:10.21037/sci.2016.06.08

  • Seiter, K., & Mamorska-Dyga, A. (2015). Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clinical Interventions in Aging, 10, 951-961. doi:10.2147/CIA.S69278

  • Lau, A., & Seiter, K. (2014). Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib. Clinical Lymphoma, Myeloma & Leukemia, 14(3), 186-196. doi:10.1016/j.clml.2013.11.002

  • Lamanna, N., Heffner, L. T., Kalaycio, M., Schiller, G., Coutre, S., Moore, J., . . . Seiter, K. (2013). Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter. Cancer, 119(6), 1186-1194. doi:10.1002/cncr.27901

  • O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., . . . Seiter, K. (2013). High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Journal of Clinical Oncology, 31(6), 676-683. doi:10.1200/JCO.2012.46.2309

  • Seiter, K. (2013). Myelodysplasia: New approaches. Current Treatment Options in Oncology, 14(2), 156-169. doi:10.1007/s11864-013-0224-x